Differential effects of adenovirus-p16 on bladder cancer cell lines can be overcome by the addition of butyrate.
High frequency of p16 alteration and high local recurrence rate of bladder cancer make this cancer an ideal target for p16 gene therapy. However, a low transduction rate of p16 via adenoviral vector causes an inconsistent result. In this study, we have tested adenovirus-p16 in several bladder cancer cell lines and investigated a way of improving the low transduction rate. Adenovirus-p16 showed a strong antitumor effect on bladder cancer cell lines (253J and T24) with strong Coxackie-adenoviral receptor (CAR) expression but little antitumor effect on bladder cancer cell lines (J82 and HT1376) with little CAR expression. In this study, we suggest a simple way of overcoming the differential effects of the adenovirus. The addition of butyrate to media was found to increase the transduction rate of adenovirus remarkably and increase the antitumor effect of adenovirus-p16 in bladder cancer cell lines with little CAR expression. Butyrate effects were related with increased CAR expression on the cell surface as well as increased transgene expression from adenoviral vector. From these observations, application of adenovirus-p16 gene therapy with butyrate can overcome the obstacle of low gene transfer and enhance the antitumor effect of adenovirus-p16 in bladder cancer.
Lee
C T
CT
Department of Internal Medicine, Lung Institute of Medical Research Center, Seoul National University College of Medicine, Seoul National University Hospital, Chongno-Gu, Korea. ctlee@snu.ac.kr
Seol
J Y
JY
Park
K H
KH
Yoo
C G
CG
Kim
Y W
YW
Ahn
C
C
Song
Y W
YW
Han
S K
SK
Han
J S
JS
Kim
S
S
Lee
J S
JS
Shim
Y S
YS
D000256:Adenoviridae / Q000187:drug effects / Q000235:genetics*; D015153:Blotting, Western; D002087:Butyrates / Q000494:pharmacology*; D002453:Cell Cycle; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D005434:Flow Cytometry; D018014:Gene Transfer Techniques; D019942:Genes, p16 / Q000235:genetics*; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D013997:Time Factors; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D002087:Butyrates